Literature DB >> 19409507

Biofilm formation in clinical Candida isolates and its association with virulence.

Fahmi Hasan1, Immaculata Xess, Xiabo Wang, Neena Jain, Bettina C Fries.   

Abstract

Biofilm formation, an important virulence trait of Candida species was measured in 107 Candida isolates from 32 candidemic patients by XTT [2,3-bis (2-methoxy-4nitro-5-sulfo-phenyl)-2H-tetra-zolium-5-carboxanilide] activity and compared to biofilm formation of Candida isolates from oropharyngeal lesions of 19 AIDS patients. Biofilm formation by XTT varied among species and C. albicans; C. lusitaniae and C. krusei produced more biofilm than the other Candida species. C. tropicalis was the most dominant species isolated from blood followed by C. albicans, and other non-albicans species whereas only C. albicans was recovered from oral lesions. Importantly, though Biofilm formation was variable within a species it was stable in sequential isolates during chronic infection. Sequential isolates exhibited identical Karyotype pattern or RAPD patterns unless patients were co-infected with more than one strain. High biofilm formation was associated with slow growth rate but not with adherence. Murine infection studies demonstrated that, degree of in-vitro biofilm formation was associated with virulence in mice, as mice infected both with no and low biofilm formers survived longer than mice infected with high biofilm former C. albicans (p< or =0.001). We conclude that biofilm formation is a stable but strain specific characteristic that can greatly vary among C. albicans and non-albicans strains, and plays an important role in persistence of infection.

Entities:  

Mesh:

Year:  2009        PMID: 19409507      PMCID: PMC2715444          DOI: 10.1016/j.micinf.2009.04.018

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  29 in total

1.  Risk factors for Candida non-albicans candidemia.

Authors:  Stijn Blot; Dominique Vandijck; Koenraad Vandewoude
Journal:  Diagn Microbiol Infect Dis       Date:  2008-03-14       Impact factor: 2.803

2.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

Authors:  J H Rex; T J Walsh; J D Sobel; S G Filler; P G Pappas; W E Dismukes; J E Edwards
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

3.  Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care.

Authors:  Stephan Harbarth; Karin Ferrière; Stéphane Hugonnet; Bara Ricou; Peter Suter; Didier Pittet
Journal:  Arch Surg       Date:  2002-12

4.  Quantitative variation of biofilms among strains in natural populations of Candida albicans.

Authors:  Xiaogang Li; Zhun Yan; Jianping Xu
Journal:  Microbiology       Date:  2003-02       Impact factor: 2.777

5.  Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces.

Authors:  D M Kuhn; J Chandra; P K Mukherjee; M A Ghannoum
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

Authors:  Gordon Ramage; Kacy VandeWalle; Stefano P Bachmann; Brian L Wickes; José L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

7.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

8.  Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms.

Authors:  G Ramage; K Vande Walle; B L Wickes; J L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

9.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

10.  Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources.

Authors:  Jong Hee Shin; Seung Jung Kee; Myung Geun Shin; Soo Hyun Kim; Dong Hyeon Shin; Sang Ku Lee; Soon Pal Suh; Dong Wook Ryang
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

View more
  58 in total

1.  Determination of the effect of Nd:YAG laser irradiation through dentinal tubules on several oral pathogens.

Authors:  Murat Maden; Güliz Görgül; M Nedim Sultan; Gülçin Akça; Ozgür Er
Journal:  Lasers Med Sci       Date:  2012-07-06       Impact factor: 3.161

Review 2.  Current status of ureteral stent technologies: comfort and antimicrobial resistance.

Authors:  Carlos E Mendez-Probst; Alfonso Fernandez; John D Denstedt
Journal:  Curr Urol Rep       Date:  2010-03       Impact factor: 3.092

Review 3.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

4.  The Activities of Adhesion and Biofilm Formation by Candida tropicalis Clinical Isolates Display Significant Correlation with Its Multilocus Sequence Typing.

Authors:  Shuan Bao Yu; Wen Ge Li; Xiao Shu Liu; Jie Che; Jin Xing Lu; Yuan Wu
Journal:  Mycopathologia       Date:  2017-01-13       Impact factor: 2.574

5.  Biofilm production by Candida: comparison of bloodstream isolates with cervical isolates.

Authors:  Sheetal U Harakuni; S G Karadesai; Nadeemaktar Jamadar
Journal:  Indian J Microbiol       Date:  2012-03-16       Impact factor: 2.461

6.  In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.

Authors:  Barbara Fiori; Brunella Posteraro; Riccardo Torelli; Mario Tumbarello; David S Perlin; Giovanni Fadda; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

7.  Structure-activity relationship study of the plant-derived decapeptide OSIP108 inhibiting Candida albicans biofilm formation.

Authors:  Nicolas Delattin; Katrijn De Brucker; David J Craik; Olivier Cheneval; Barbara De Coninck; Bruno P A Cammue; Karin Thevissen
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

8.  Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates.

Authors:  Jianlan You; Lin Du; Jarrod B King; Brian E Hall; Robert H Cichewicz
Journal:  ACS Chem Biol       Date:  2013-02-14       Impact factor: 5.100

9.  Candida albicans and non-C. albicans Candida species: comparison of biofilm production and metabolic activity in biofilms, and putative virulence properties of isolates from hospital environments and infections.

Authors:  A V Ferreira; C G Prado; R R Carvalho; K S T Dias; A L T Dias
Journal:  Mycopathologia       Date:  2013-03-27       Impact factor: 2.574

10.  Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.

Authors:  Maria Simitsopoulou; Pavla Peshkova; Efthymia Tasina; Aspasia Katragkou; Daniela Kyrpitzi; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.